Product Reports Resources Pricing Login Book a demo

Prometheus Biosciences

Biotech & Life Sciences · San Diego, United States · Founded 1995 · IPO 2021

Committed to the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune disease

Valuation $8.87B
Revenue $6.8M
Power Law Unicorn$1–10B valuation tier

Investors

10 investors on Prometheus Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 10 investors entered at this stage
Ascend Global Investments
Nestlé
Cowen Group
RTW Investments
Eventide Asset Management
Perceptive Advisors
Cormorant Capital
Cedars-Sinai
Irving Investors
Point72

Prometheus Biosciences mafia

Startups founded by Prometheus Biosciences alumni

Former Prometheus Biosciences employees who went on to start their own companies. Sorted by Dealroom signal score.

Mirador TherapeuticsEst. 2024
MMMark McKennaUnited States
Signal score92
Phathom PharmaceuticalsEst. 2018
David SocksUnited States
Signal score75
SantarusEst. 1996
Scott GlennUnited States
Signal score70
Shoreline BiosciencesEst. 2020
William SandbornUnited States
Signal score61

Book a demo to explore the full alumni network →

Global footprint

Where Prometheus Biosciences has talent and traffic

Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Talent graph

The shape of Prometheus Biosciences's talent

Dealroom maps Prometheus Biosciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Prometheus Biosciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$52M patent portfolio · 57 active families

Estimated portfolio value
$52M
0.59% of market cap · 4.3× smaller than top peer Xencor ($227M)
57 active patent families
Where Prometheus Biosciences innovates Antiendomysial antibodiesAutoimmune inflammatory bowel diseaseBowels diseasesInflammatory bowel diseaseMolecular biology

Where Prometheus Biosciences concentrates vs peers

Each axis is a top-10 topic across Prometheus Biosciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Prometheus Biosciences

An AI-synthesized read of the highest-engagement posts about Prometheus Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Prometheus Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles